- Home
- IVP vs TNFA Comparison
IVP vs TNFA Comparison
Compare IVP & TNFA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IVP
- TNFA
- Stock Information
- Founded
- IVP 2020
- TNFA 2014
- Country
- IVP United States
- TNFA United States
- Employees
- IVP N/A
- TNFA N/A
- Industry
- IVP Diversified Commercial Services
- TNFA
- Sector
- IVP Miscellaneous
- TNFA
- Exchange
- IVP Nasdaq
- TNFA NYSE
- Market Cap
- IVP 3.0M
- TNFA 3.2M
- IPO Year
- IVP 2023
- TNFA N/A
- Fundamental
- Price
- IVP $2.08
- TNFA $0.48
- Analyst Decision
- IVP
- TNFA
- Analyst Count
- IVP 0
- TNFA 0
- Target Price
- IVP N/A
- TNFA N/A
- AVG Volume (30 Days)
- IVP 139.9K
- TNFA 852.2K
- Earning Date
- IVP 04-07-2025
- TNFA 03-31-2025
- Dividend Yield
- IVP N/A
- TNFA N/A
- EPS Growth
- IVP N/A
- TNFA N/A
- EPS
- IVP N/A
- TNFA N/A
- Revenue
- IVP $17,054,777.00
- TNFA N/A
- Revenue This Year
- IVP N/A
- TNFA N/A
- Revenue Next Year
- IVP N/A
- TNFA N/A
- P/E Ratio
- IVP N/A
- TNFA N/A
- Revenue Growth
- IVP 6.12
- TNFA N/A
- 52 Week Low
- IVP $2.00
- TNFA $0.45
- 52 Week High
- IVP $401.50
- TNFA $3.60
- Technical
- Relative Strength Index (RSI)
- IVP 26.11
- TNFA 26.35
- Support Level
- IVP $2.03
- TNFA $0.45
- Resistance Level
- IVP $2.20
- TNFA $0.66
- Average True Range (ATR)
- IVP 0.19
- TNFA 0.09
- MACD
- IVP 0.07
- TNFA -0.00
- Stochastic Oscillator
- IVP 11.19
- TNFA 7.07
About IVP Inspire Veterinary Partners Inc.
Inspire Veterinary Partners Inc owns and operates veterinary hospitals throughout the United States. The company specializes in small animal general practice hospitals that serve all manner of companion pets, emphasizing canine and feline breeds.
About TNFA TNF PHARMACEUTICALS INC EFFEC
TNF Pharmaceuticals Inc is a clinical-stage pharmaceutical company committed to extending a healthy lifespan. The company is developing and commercializing two therapeutic platforms. MyMD-1 is a small molecule that regulates the immunometabolic system to treat autoimmune diseases, including multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel disease. It is being developed to treat age-related illnesses such as frailty and sarcopenia. Supera-CBD is a synthetic derivative of CBD being developed to treat various conditions, including epilepsy, pain, and anxiety/depression, through its effects on the CB2 receptor, opioid receptors, and monoamine oxidase enzyme type B.